Financials data is unavailable for this security.
View more
Year on year Astec Lifesciences Ltd 's revenues fell -27.06% from 6.28bn to 4.58bn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a gain of 255.65m to a loss of 469.30m.
Gross margin | 22.47% |
---|---|
Net profit margin | -20.38% |
Operating margin | -23.74% |
Return on assets | -- |
---|---|
Return on equity | -- |
Return on investment | -- |
More ▼
Cash flow in INRView more
In 2024, Astec Lifesciences Ltd did not generate a significant amount of cash. Cash Flow from Financing totalled 1.48bn or 32.34% of revenues. In addition the company generated 102.21m in cash from operations while cash used for investing totalled 1.35bn.
Cash flow per share | -21.57 |
---|---|
Price/Cash flow per share | -- |
Book value per share | -- |
---|---|
Tangible book value per share | -- |
More ▼
Balance sheet in INRView more
Current ratio | -- |
---|---|
Quick ratio | -- |
Total debt/total equity | -- |
---|---|
Total debt/total capital | -- |
More ▼
Growth rates in INR
Year on year, growth in earnings per share excluding extraordinary items dropped -283.56%.
Div yield(5 year avg) | 0.14% |
---|---|
Div growth rate (5 year) | -- |
Payout ratio (TTM) | -- |
EPS growth(5 years) | -- |
---|---|
EPS (TTM) vs TTM 1 year ago | -1,413.51 |
More ▼